Researchers led by Université de Montréal pathology and cell-biology professor Marc Therrien have identified major structural changes that enable the BRAF protein to escape control and mimic its ...

Later this year, these ad formats will expand globally to select countries on both mobile and desktop, focusing on English-language queries. Google is also testing ads in AI Mode, the company’s ...

C4 Therapeutics is sawing off another part of its solely owned pipeline, this time ending work on its clinical-stage BRAF degrader program in order to focus on its IKZF1/3 degrader cemsidomide.

A novel topical BRAF inhibitor gel, LUT014, significantly reduced the severity of an acne-like rash caused by anti-EGFR therapies in patients with colorectal cancer, according to researchers from UCLA ...

Heterogeneity of genomic instabilities among individual patients is believed to be a major cause of drug response heterogeneity. Cancer patients who are sensitive to anti-cancer drugs are often ...

BRAF-positive non-small cell lung cancer (NSCLC) treatments can use the BRAF biomarker to provide effective, targeted treatment for this subset of lung cancer.

Pfizer is trying to increase doctor awareness of and testing for a rare lung cancer mutation to help boost use of its drug Braftovi, which the pharmaceutical maker anticipates could grow to become ...

A new research perspective was published in Oncotarget's Volume 15 on July 16, 2024, entitled, “Targeting the multifaceted BRAF in cancer: New directions.” ...

Mode of action Source; L743F: BRAF L485F: Extended hydrophobic interaction network along the αC-helix: Hu et al., 2015: F761[H/M] BRAF L505[F/H/M] Enforcement of hydrophobic interactions in the ...

In patients with BRAF V600E mutation (n=12), the ORR was 50%. Results also showed an ORR of 49% among patients who had prior MAPK-targeted therapy (n=45), and 55% among patients who did not ...

Against this backdrop, Pfizer’s Braftovi (encorafenib) is positioned to secure a dominant 42% share of the BRAF inhibitors market for melanoma by 2028, underscoring its pivotal role in cancer ...

Combined BRAF and MEK1/2 inhibition prevents reactivation of the pathway, but tumors tend to return. In PTC patients, meanwhile, there is no effective drug to target BRAF. Advanced ...